3rd Jun 2005 12:40
VASTox plc03 June 2005 Immediate Release 3 June 2005 VASTox plc ("VASTox" or "the Company") RESULT of AGM Oxford, UK: 3 June 2005 - VASTox plc (AIM: VOX), the Oxford-based drug discoveryand services business focused on chemical genomics, is pleased to announce thatall of the resolutions at the AGM of the Company, held today, were duly passed. Professor Stephen Davies, Non-Executive Chairman of Vastox, commented: "Sinceour successful flotation on AIM in October last year the Company has madesignificant progress with its proprietary programmes in Duchenne MuscularDystrophy and Tuberculosis. Vastox has also signed several new service deals,relocated to new facilities in Oxfordshire and strengthened its ScientificAdvisory Board in key areas of technology and drug development. The business isin a strong position for future growth." --ENDS-- Contact details: VASTox 07766 913898Steven Lee, Chief Executive Officer Buchanan Communications 020 7466 5000Tim Anderson / Mark Court / Mary-Jane Johnson Notes for Editors: About VASTox VASTox is a chemical genomics technology company that both provides services tothe pharmaceutical industry, and discovers and develops proprietary novel drugs.The company's technology platform aims to use high volume, high contentscreening using zebrafish and fruitflies to provide a high level ofpredictability of the efficacy and toxicity of potential drug compounds inhumans which has the potential to dramatically decrease the time and cost ofdrug discovery and development. VASTox was formed in January 2003, from theUniversity of Oxford, by some of the UK's foremost scientists who have taken ahighly creative approach to the problems involved in drug discovery and who havea proven record in delivering technological excellence. The company listed onthe London Stock Exchange AIM in October 2004. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SUMM.L